A Case Report of Deglutition Triggered Atrial Fibrillation in a Patient with Laing Distal Myopathy
Chikezie K. Alvarez, MD¹; Heather Swales, MD¹, Jeffrey Kluger, MD¹
Cardiovascular Department, Hartford Hospital/University of Connecticut
80 Seymour St, Hartford, CT 06106, USA

Corresponding Author
Chikezie K. Alvarez MD
20 Front Street, Apt 510
Hartford, CT 06103, USA
Email – chikezie.alvarez@hhchealth.org; chikeziealvarez@gmail.com
Phone – 347 698 2388

Funding – None

Keywords – Case report; Deglutition triggered atrial fibrillation; Laing Distal Myopathy; wide complex tachycardia; flecainide and non-dihydropyridine calcium channel blockers

Author Contributions:
Chikezie Alvarez – Direct patient care, manuscript drafting, critical revision and gave final approval to be published.
Heather Swales - Direct patient care, critical manuscript revision and gave final approval to be published.
Jeffrey Kluger - Direct patient care, critical manuscript revision and gave final approval to be published.

Conflict of interest: None declared.
Learning Points

1. Recognize the unusual association of deglutition induced atrial fibrillation in a patient with Laing distal myopathy.

2. Flecainide in combination with non-beta blocker atrioventricular blocking agents such as verapamil can be effectively used for the treatment of vagally mediated atrial fibrillation.
32 Years Old Diagnosed with Laing Distal myopathy: result of mutations within the slow skeletal muscle fiber myosin heavy chain gene (*MYH7*).

44 years old Episodic palpitations and pre-syncope after deglutition.

30-day patient triggered event monitor recorded episodes of atrial fibrillation with rapid ventricular response occurring post deglutition.

Normal TSH, TTE, Cardiac MRI and vasodilator SPECT imaging stress test.

40 days later after initial symptoms: initiated on flecainide and verapamil with no further recurrence of atrial fibrillation.
Introduction

Deglutition induced atrial fibrillation is a rare clinical entity with approximately 50 reported cases since its initial description in 1926 and a reported prevalence of 0.6\%\(^1\)–\(^3\). Laing distal myopathy is a rare autosomal dominant muscular dystrophy with an unknown prevalence that is the result of mutations within the slow skeletal muscle fiber myosin heavy chain gene (\textit{MYH7}). We describe the first reported case of deglutition triggered atrial fibrillation in a middle-aged female who has a history of Laing distal myopathy.

Case Presentation

A 44-year-old-female with a past medical history of hyperlipidemia and Laing distal myopathy diagnosed at age 32, began experiencing intermittent episodes of pre-syncope and palpitations which occurred intermittently after swallowing, predominantly during deglutition with food. Episodes of palpitations and pre-syncope post deglutition occurred mostly with warm liquids or food intake and less frequently with cold liquids. There was no accompanying chest pain, shortness of breath or odynophagia. She did not consume alcohol, caffeine and was a non-smoker. An ambulatory 30-day patient triggered event monitor recorded episodes of atrial fibrillation with rapid ventricular response (\textit{Figure 1}) and wide-complex tachycardia with heart rates up to 242 beats per minute (\textit{Figure 2}). Each patient triggered event occurred after eating, associated with lightheadedness and/or palpitations. Family history was significant for Laing distal myopathy in her father who is still alive at 72 years old and atrial fibrillation in her mother.
Given the findings on ambulatory event monitoring, she was admitted to our hospital for further evaluation. Patient blood pressure on presentation was 123/64 mmHg, pulse 76 beats/minute and regular, respiration rate 18 breaths/minute, weight 109 pounds and BMI of 22.07 kg/m². Oxygen saturation was 100% on ambient air. Remainder of the physical exam including respiratory exam was unremarkable. Laboratory data including a complete metabolic panel, troponin I, N-terminal pro-BNP, and thyroid function tests were within normal limits. Resting baseline electrocardiogram demonstrated sinus rhythm, right axis deviation. Transthoracic echocardiogram and cardiac MRI were normal. An exercise treadmill SPECT Imaging stress test revealed normal left ventricular systolic function and no evidence of ischemia or infarction. A fluoroscopic esophagram revealed a mild esophageal dysmotility.

During hospitalization, she had several episodes of atrial fibrillation with rapid ventricular response which coincided with deglutination. She was initially placed on metoprolol tartrate 12.5 mg twice daily with mild improvement of palpitations; however, she was still experiencing episodes of atrial fibrillation with rapid ventricular response after deglutination. Metoprolol tartrate was subsequently discontinued, and she was started on flecainide 50 mg po every 8 hours and verapamil 40 mg po every 8 hours. During her hospitalization, there were no recorded episodes of ventricular tachycardia. After initiation of flecainide and verapamil, there has been no documented recurrence of atrial fibrillation and her symptoms of palpitations have resolved.
Discussion:

Laing distal myopathy is a rare autosomal dominant muscular dystrophy caused by mutations within the myosin heavy chain gene 7 (MYH7). The MYH7 gene encodes a beta-myosin heavy chain isoform that is expressed primarily in the heart and also in type I skeletal muscle fibres. Mutations in the MYH7 gene is associated with various cardiac conditions including myosin storage myopathy, left ventricular non-compaction, familial restrictive, dilated and hypertrophic cardiomyopathy.

Atrial fibrillation has been previously associated with several other myopathies including myotonic dystrophy type I, Emery–Dreifuss muscular dystrophy, as well as Duchenne and Becker muscular dystrophies. After an extensive review of the literature, we could not find any previous reports of atrial fibrillation in patients who were diagnosed with Laing myopathy. Thus far, the only previously reported cardiac involvement in a patient with Laing myopathy was one report of a cardiomegaly, however no reports of atrial arrhythmias.

Emerging evidence which supports a genetic and familial basis for atrial fibrillation, is becoming increasingly recognized and is an area of research. Variants in genes encoding ion channel subunits, cardiac gap junctions, as well as loss in cytoskeletal proteins such as cytoskeletal protein 4.1R have been implicated in the arrhythmogenesis associated with atrial fibrillation. Given the strong genetic component of this myopathy, one could postulate as to a possible genetic component in the development of atrial fibrillation in our patient. Furthermore, given the family history of our patient which includes paternal Laing myopathy and maternal history of atrial fibrillation, future studies may better elucidate the shared genetic component of patients with atrial fibrillation.
Although the pathophysiology behind deglutition triggered atrial fibrillation has not been fully elucidated, various mechanisms have been proposed. One such mechanism involves direct vaso-vagal parasympathetic stimulation via the afferent and efferent branches of the vagus nerve. These branches are activated during a rise in intra-esophageal pressure with preferential vagal discharges to the atria and not the sinus node, triggering atrial fibrillation without precipitation of bradycardia\(^9\). Vagal activation can also reduce the atrial effective refractory period\(^10\).

Initial management of deglutition induced atrial fibrillation involves avoidance of food triggers, limiting large food boluses, caffeine, and alcohol use. For recurrent deglutition triggered atrial fibrillation despite conservative changes, pharmacologic medications can be considered. There is no universally agreed upon treatment for swallowing induced atrial fibrillation however class IC agents including propafenone or flecainide have been shown to be effective\(^11,12\). Amiodarone has also been successfully used,\(^11\) however, given the potential long term adverse effects, we opted to not use this agent in our relatively young patient. We therefore choose to prescribe flecainide given the lack of structural heart disease in our patient. In addition, we added a non-dihydropyridine calcium channel blocker verapamil to decrease the risk of 1:1 AV conduction with flecainide\(^13\). Verapamil can also provide a degree of suppression of triggered activity which might be responsible for atrial arrhythmogenesis.

Catheter ablation with pulmonary vein isolation (PVI) has been attempted successfully, although it has been reserved mostly for cases which are refractory to medical treatment\(^14,15\). Given the potential role that the autonomic nervous system may have in vagally mediated atrial fibrillation, catheter ablation of ganglionated plexi
(GP), may potentially be curative for these patients. Calo et al. successfully utilized ablation of the GP in the right atrium in patients with vagally mediated atrial fibrillation\textsuperscript{16}. Utilizing activation mapping of the left atrium to detect atrial tachycardia during swallowing, Challapudi and colleagues were able to perform PVI of the right superior pulmonary vein and right anterior GP with resolution of symptoms in follow up\textsuperscript{1}. Lastly, combined PVI along with GP ablation have shown inconsistent results, however increased success has been seen in patients with more pronounced autonomic triggers for atrial fibrillation\textsuperscript{17}. Our patient wanted to avoid an invasive treatment approach and given that she was well controlled with medications, this was reasonable.

We choose against oral anticoagulation for our patient given that she had no risk factors other than being female which traditionally would give her a CHA\textsubscript{2}DS\textsubscript{2}-VASC of 1. Without any additional risk factors, female sex is only a risk modifier, is age dependent, and there is no difference in stroke risk based on gender alone\textsuperscript{13}. Our patient was well controlled on both flecainide 50 mg orally every 8 hours and verapamil 40 mg orally every 8 hours with no further symptoms or documented recurrence of atrial fibrillation on subsequent 30-day cardiac event monitoring 1 year later.
References

1. Challapudi G, Gabriels J, Rabinowitz E, Blaufox AD, Patel A. Swallowing-induced atrial tachycardia in an adolescent with hypertrophic cardiomyopathy: a case report. Eur Hear J - Case Reports; 1. Epub ahead of print 1 August 2017. DOI: 10.1093/ehjer/yt004.

2. Sakai, Mori F. Über einen Fall von sog. „Schlucktachykardie“. Z Gesamte Exp Med 1926; 50: 106–109.

3. Tada H, Kasenko K, Kubota S, Naito S, Yokokawa M, Hiramatsu S, et al. Swallowing-Induced Atrial Tachyarrhythmias: Prevalence, Characteristics, and the Results of the Radiofrequency Catheter Ablation. Pacing Clin Electrophysiology 2007; 30: 1224–1232.

4. Zhang S, Wilson J, Madani M, Feld G, Greenberg B. Atrial Arrhythmias and Extensive Left Atrial Fibrosis as the Initial Presentation of MYH7 Gene Mutation. JACC Clin Electrophysiology 2018; 4: 1488–1490.

5. Lamont PJ, Udd B, Mastaglia FL, de Visser M, Hedera P, Voit T, et al. Laing early onset distal myopathy: slow myosin defect with variable abnormalities on muscle biopsy. J Neurology Neurosurgery Psychiatry 2006; 77: 208–15.

6. Hedera P, Petty EM, Bui MR, Blaivas M, Fink JK. The second kindred with autosomal dominant distal myopathy linked to chromosome 14q: Genetic and clinical analysis. Arch Neurology 2003; 60: 1321–1325.

7. Cunha SR, Mohler PJ. Cardiac cytoskeleton and arrhythmia: An unexpected role for protein 4.1R in cardiac excitability. Circulation Research 2008; 103: 779–781.

8. Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation. Circ Res 2014; 114: 1469–1482.

9. Suarez LD, Chiozza MA, Foye R, Mosso H, Perosio AM. Swallowing-dependent atrial tachyarrhythmias. Their mechanism. J Electrocardiology 1980; 13: 301–305.

10. Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circulation Research 2014; 114: 1004–1021.

11. Khalid U, Massumi A, Shaibani A. Swallowing-induced Supraventricular Tachyarrhythmia. Rev Cardiovasc Med 2017; 18: 53–58.

12. Wilmshurst PT. Tachyarrhythmias triggered by swallowing and belching. Heart 1999; 81: 313.

13. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140: e125–e151.

14. Undavia M, Sinha S, Mehta D. Radiofrequency ablation of swallowing-induced atrial tachycardia: Case report and review of literature. Hear Rhythm 2006; 3: 971–974.

15. Yamauchi Y, Aonuma K, Sekiguchi Y, Higuchi K, Obayashi T, Isobe M. Curative therapy for
swallowing-induced tachycardia by pulmonary vein antrum isolation. *J Cardiovasc Electrophysiology* 2005; 16: 1370–1374.

16. Calò L, Rebecchi M, Sciarrà L, De Luca L, Fagagnini A, Zuccaro LM, et al. Catheter ablation of right atrial ganglionated plexi in patients with vagal paroxysmal atrial fibrillation. *Circ Arrhythmia Electrophysiology* 2012; 5: 22–31.

17. Shen MJ, Zipes DP. Role of the Autonomic Nervous System in Modulating Cardiac Arrhythmias. *Circ Res* 2014; 114: 1004–1021.

**Consent:** The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

**Figure Legends**

1. **Figure 1.** Ambulatory patient triggered cardiac event strip demonstrating atrial fibrillation with rapid ventricular response at 170 beats per minute. Event was triggered after deglutition.

2. **Figure 2.** Ambulatory patient triggered cardiac event which reveals sinus rhythm with 75 beats per minute followed by 13 beats of wide-complex tachycardia at 242 beats per minute. Event was triggered after deglutition.
Figure 2. Ambulatory patient triggered cardiac event which reveals sinus rhythm with 75 beats per minute followed by 13 beats of wide-complex tachycardia at 242 beats per minute.
Figure 1. Ambulatory patient triggered cardiac event strip demonstrating atrial fibrillation with rapid ventricular response at 170 beats per minute. Event was triggered...